Navigation Links
In the real life setting, boosted REYATAZ proves as effective in women living with HIV as men
Date:7/20/2011

(ROME, 20 July 2011) Bristol-Myers Squibb Company announced results from a long-term, retrospective, European cohort study, which included 1,294 antiretroviral (ARV)-experienced patients (336 female and 958 male) from Germany, France and Sweden, that were presented today at the Sixth International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2011).

In a gender-specific sub-analysis, boosted REYATAZ (atazanavir sulphate) (ATV/ritonavir)-based regimens demonstrated no difference in time to virologic failure in women compared to men over a follow-up period of up to five years.2

Approximately 30 years into the AIDS epidemic, nearly 16 million women are living with HIV, and most of them are of childbearing age.3 HIV has become the leading cause of disease and death among women of reproductive age worldwide.4 In Europe, women account for 35% of new HIV diagnoses.1 However, data on efficacy, safety and tolerability on antiretrovirals (ARVs) in women are limited, as they are under-represented in clinical trials.5

"More clinical data, especially long-term data, evaluating ARV response in women with HIV are needed to improve their management; in this way, the results presented today give us as physicians relevant and valuable information," said Prof. Dr Norbert H. Brockmeyer, Germany.

This retrospective, observational study collected data from three European databases (France DatAids; Germany KompNet; Sweden InfCare). All participants were ARV-treatment experienced patients; 336 female (median age of 40 years) and 958 male (median age of 44 years).2 The present sub-analysis evaluated the effect of gender on long-term outcomes of ATV/r-based regimens.

The results revealed no gender-based differences in time to virological failure, defined as two consecutive HIV RNA ≥ 50 c/mL or one HIV RNA ≥ 50 c/mL followed by discontinuation. After three years of follow-up, the probability of not having virological failure was 59% for women (95% CI 52-65%) and 63% for men (95% CI 59-67%). As seen in several other recent studies,6,7 female gender was associated with increased risk of treatment discontinuation but not with a significantly higher risk of virologic failure.2

The cohort results also showed that REYATAZ/ritonavir is a well-tolerated therapeutic option for treatment-experienced patients of either gender.2 Overall, the safety profile was comparable among men and women and similar to that previously described in clinical trials. Among women, diarrhoea was reported in 2%, nausea in < 1%, jaundice in < 1%, lipodystrophy in 5% and bone density abnormalities in < 1% of the cases.2

The results reported in this gender-specific sub-analysis are consistent with those previously reported in clinical trials (i.e CASTLE study gender analysis) in which boosted REYATAZ showed durable viral suppression and favourable safety and tolerability profiles, irrespective of gender.


'/>"/>

Contact: Joanna Ritter
33-015-883-6509
TogoRun
Source:Eurekalert

Related medicine news :

1. Animal-assisted therapy decreases patient anxiety in pre-MRI setting, study suggests
2. Hispanic Aesthetics Boosted by Dr. Mark Berman, President of the American Academy of Cosmetic Surgery
3. Sexual, Urinary Health Boosted in Exercisers, Nonsmokers
4. Study shows durable viral suppression of boosted REYATAZ in treatment-experienced HIV patients
5. A New Website Series Improves Appearance and Health City by City
6. Kaiser Permanente Approves $170 Million in Community Benefit Grants in 2009
7. Behavioral therapy improves sleep and lives of patients with pain
8. New Successful Treatment Improves Walking Post Stroke
9. Short on specialized intensive care physicians, team-based approach improves ICU outcomes
10. Belief in a caring god improves response to medical treatment for depression
11. Combined drug therapy to treat TB and HIV significantly improves survival
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... agency serving communities in the greater Dallas, Miami, and Raleigh regions, is organizing ... fighting to overcome a rare and deadly chromosome abnormality. , After struggling since ...
(Date:10/13/2017)... WI (PRWEB) , ... October 13, 2017 , ... As ... in medicine known as “patient engagement.” The patient is doing more than filling out ... partners. , “There is an increasing emphasis in health care and research on ...
(Date:10/13/2017)... ... October 13, 2017 , ... The American Board of Family Medicine's (ABFM) ... and Chief Executive Officer, succeeding Dr. James C. Puffer upon his retirement. Dr. Newton ... until Dr. Puffer’s retirement at the end of 2018. Upon assuming the role of ...
(Date:10/13/2017)... ... October 13, 2017 , ... PurhealthRX , a leading Health and Nutrition ... the Purzorb™process to full spectrum CBD oil will revolutionize the rapidly growing CBD market ... can be easily incorporated into liquid products, while reducing costs to end users. , ...
(Date:10/13/2017)... ... , ... Lori R. Somekh, founder of the Law Office of Somekh ... law and special needs planning attorneys. “Membership in ElderCounsel helps our office remain up ... network with elder law attorneys nationwide,” said Somekh. , ElderCounsel was ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)...  Eli Lilly and Company (NYSE: LLY ... quarter of 2017 on Tuesday, October 24, 2017. Lilly ... with the investment community and media to further detail ... will begin at 9 a.m. Eastern time. Investors, media ... of the conference call through a link that will ...
(Date:10/2/2017)... , Oct. 2, 2017 The Rebound mobile app ... struggle to reverse the tide of prescription drug addiction. The ... their medicine intake and stepping down their dosage in a ... launch in December 2017; the first 100,000 people to sign ... at http://www.rebound-solution.com/ ...
(Date:9/27/2017)... MIAMI , Sept. 27, 2017  Commended for their ... recent notable awards. Ranked as number one in the South ... ninth time in Inc. 5000 yearly list, the national specialty ... CEO, Armando Bardisa will soon be honored by ... Set to receive his award ...
Breaking Medicine Technology: